Search by Drug Name or NDC
NDC 61958-2301-01 VEMLIDY 25 mg/1 Details
VEMLIDY 25 mg/1
VEMLIDY is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Gilead Sciences, Inc.. The primary component is TENOFOVIR ALAFENAMIDE FUMARATE.
MedlinePlus Drug Summary
Tenofovir is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 2 years of age and older. Tenofovir is also used to treat chronic (long term) HBV in adults and children 2 years of age and older weighing 22 pounds (10 kilograms) or more. Tenofovir is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV and HBV in the blood. Although tenofovir will not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting the HIV virus to other people. Tenofovir will not cure hepatitis B and may not prevent complications of chronic hepatitis B such as cirrhosis of the liver or liver cancer. Tenofovir may not prevent the spread of hepatitis B to other people.
Related Packages: 61958-2301-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Tenofovir
Product Information
| NDC | 61958-2301 |
|---|---|
| Product ID | 61958-2301_2601d778-99cc-4b50-9c39-a5c0559cfc03 |
| Associated GPIs | 12352083200320 |
| GCN Sequence Number | 076823 |
| GCN Sequence Number Description | tenofovir alafenamide TABLET 25 MG ORAL |
| HIC3 | W5F |
| HIC3 Description | HEPATITIS B TREATMENT AGENTS |
| GCN | 42624 |
| HICL Sequence Number | 043907 |
| HICL Sequence Number Description | TENOFOVIR ALAFENAMIDE |
| Brand/Generic | Brand |
| Proprietary Name | VEMLIDY |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | tenofovir alafenamide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 25 |
| Active Ingredient Units | mg/1 |
| Substance Name | TENOFOVIR ALAFENAMIDE FUMARATE |
| Labeler Name | Gilead Sciences, Inc. |
| Pharmaceutical Class | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleosides [CS] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA208464 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 61958-2301-01 (61958230101)
| NDC Package Code | 61958-2301-1 |
|---|---|
| Billing NDC | 61958230101 |
| Package | 30 TABLET in 1 BOTTLE, PLASTIC (61958-2301-1) |
| Marketing Start Date | 2016-11-10 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 46.4125 |
| Pricing Unit | EA |
| Effective Date | 2024-01-01 |
| NDC Description | VEMLIDY 25 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |